CANCER THERAPEUTIC INSIGHTS

162 Pharmacologic Blockade of FAK Autophosphorylation Decreases Human Glioblastoma Tumor Growth and Synergizes with Temozolomide Vita M. Golubovskaya, Grace Huang, Baotran Ho, Michael Yemina, Carl D. Morrison, Jisook Lee, Brian F. Eliezeiri, and William G. Cance

173 Induction of Endoplasmic Reticulum Stress by Sorafenib and Activation of NF-κB by Lestaurotinib as a Novel Resistance Mechanism in Hodgkin Lymphoma Cell Lines Mei Ke Stefanie Holz, Angela Janning, Christoph Renne, Stefan Gattenbihlner, Tilman Spieker, and Andreas Bräuninger

184 Triptolide Inhibits MDM2 and Induces Apoptosis in Acute Lymphoblastic Leukemia Cells through a p53-Independent Pathway Mei Huang, Hailong Zhang, Tao Liu, Dan Tian, Lubing Gu, and Muxiang Zhou

195 Bortezomib Sensitizes Human Acute Myeloid Leukemia Cells to All-Trans-Retinoic Acid–Induced Differentiation by Modifying the RARα/STAT1 Axis Meidan Ying, Xinglu Zhou, Like Zhong, Nengming Lin, Hui Jing, Feihua Luo, Xiaochun Yang, Hua Song, Bo Yang, and Qiaojun He

207 miRNA-100 Inhibits Human Bladder Urothelial Carcinogenesis by Directly Targeting mTOR Chuanliang Xu, Qin Song Zeng, Weidong Xu, Li Jiao, Yangqiong Chen, Zhensheng Zhang, Chengyao Wu, Taile Jin, Anyin Pan, Rongchao Wei, Bo Yang, and Yinghao Sun

COMPANION DIAGNOSTICS AND BIOMARKERS

220 EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics Maria E. Arcila, Khedoudja Nafa, Jamie E. Chaft, Natasha Reva, Christopher Lau, Boris A. Reva, Maureen F. Zakowski, Mark G. Kris, and Marc Ladanyi
Antitumor Activity and Pharmacodynamic Biomarkers of a Novel and Orally Available Small-Molecule Antagonist of Inhibitor of Apoptosis Proteins

Hiroyuki Sumi, Masato Yabuki, Kenichi Iwai, Megumi Morimoto, Ryosuke Hibino, Masakazu Inazuka, Kentaro Hashimoto, Yohei Kosugi, Kazunobu Aoyama, Shunsuke Yamamoto, Mie Yoshimatsu, Hideki Yamasaki, Ryuichi Tozawa, Tomoyasu Ishikawa, and Sei Yoshida

Correction: TPI-287, a New Taxane Family Member, Reduces the Brain Metastatic Colonization of Breast Cancer Cells

ABOUT THE COVER

In silico molecular modeling of the EGFR exon 20 A763_Y764 insertion mutation. Mutations in this region are predicted to cause significant rearrangement of the C helix (yellow) but do not affect the erlotinib binding pocket directly (erlotinib shown in green). Insertions in EGFR exon 20 that are more distal (3') are expected to result in a greater obstructive effect on erlotinib binding. These predictions suggest a basis for the observed variability of response to EGFR inhibition in patients with different types of EGFR exon 20 insertions. For details, see article by Arcila and colleagues on page 220.